H.R. 8574 118th Congress
340B ACCESS Act
- Health
- Sponsor: Rep. Bucshon, Larry [R-IN-8]
- Congress.gov ↗
Latest action, Dec 17, 2024: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
2 cosponsors
Sponsored by Rep. Bucshon, Larry [R-IN-8] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
0 D · 2 R
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
3 reports
3 reports
3 reports
3 reports
3 reports
3 reports
3 reports
JOB CREATORS NETWORK
HARNED STRATEGIES LLC
3 reports
3 reports
3 reports
3 reports
3 reports
All 25 of 36 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| 340B HEALTH | 3 | $921K | Q4 2024 | Q3 2024 | yes | |
| ADVOCATES FOR COMMUNITY HEALTH | 3 | $240K | Q4 2024 | Q3 2024 | yes | |
| AMERICAN HOSPITAL ASSOCIATION | 3 | $18.1M | Q4 2024 | Q3 2024 | yes | |
| AMGEN INC | 3 | $8.3M | Q4 2024 | Q3 2024 | yes | |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 3 | $2.0M | Q4 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 3 | $4.9M | Q4 2024 | Q3 2024 | yes | |
| CALIFORNIA HOSPITAL ASSOCIATION | 3 | $1.1M | Q4 2024 | Q3 2024 | yes | |
| DAIICHI SANKYO INC | 3 | $1.1M | Q4 2024 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 3 | $4.0M | Q4 2024 | Q3 2024 | yes | |
| JOB CREATORS NETWORK | HARNED STRATEGIES LLC | 3 | $23K | Q4 2024 | Q3 2024 | yes |
| JOHNSON & JOHNSON SERVICES INC | 3 | $5.0M | Q4 2024 | Q3 2024 | yes | |
| LUNDBECK LLC | 3 | $420K | Q4 2024 | Q3 2024 | yes | |
| NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 3 | $3.2M | Q4 2024 | Q3 2024 | yes | |
| NATIONWIDE CHILDREN'S HOSPITAL INC | 3 | $125K | Q4 2024 | Q3 2024 | yes | |
| NEW YORK AND PRESBYTERIAN HOSPITAL | 3 | $340K | Q4 2024 | Q3 2024 | yes | |
| PFIZER INC. | 3 | $5.1M | Q4 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 3 | $21.4M | Q4 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | W STRATEGIES, LLC | 3 | $0 | Q4 2024 | Q3 2024 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | DESIMONE CONSULTING, LLC | 3 | $90K | Q4 2024 | Q3 2024 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 3 | $2.4M | Q4 2024 | Q3 2024 | yes | |
| THE HEMOPHILIA ALLIANCE | ARTEMIS POLICY GROUP LLC | 3 | $120K | Q4 2024 | Q3 2024 | yes |
| THE METROHEALTH SYSTEM | 3 | $410K | Q4 2024 | Q3 2024 | yes | |
| TRINITY HEALTH | 3 | $600K | Q4 2024 | Q3 2024 | yes | |
| UNIVERSITY OF TOLEDO | VAN SCOYOC ASSOCIATES | 3 | $80K | Q4 2024 | Q3 2024 | — |